

Janssen: Our commitment to Neuroscience

At Janssen Neuroscience, we have an ambitious goal – to ensure a future where we can predict and prevent some of humankind’s most devastating and debilitating nervous system disorders.

The facts



Neurological conditions in Europe:

Approximately
3 in 5 people
in Europe are living
with a neurological condition¹

Are the
3rd most
common cause
of disability and premature death²



Affect
307 million
people live with
a neurological condition^{1,2}

Are growing in prevalence with
74.5 million
new diagnoses each year^{1,2}

Leading the way through innovation



Janssen’s neuroscience portfolio is **focused on the areas where we can make the biggest difference.**

Our portfolio and pipeline cover the following conditions:

Neuropsychiatric

Neurological

Neurodegenerative

Auto-antibody driven diseases



Over 60 years of life changing discoveries



Dr Paul Janssen



Since the launch of our **first pioneering psychiatric therapy in 1958**, Janssen has delivered **more than 20 therapies** and innovations for neuropsychiatric and neurodegenerative conditions.³

1958

Dr Paul Janssen develops a pioneering therapy for schizophrenia

1960s

Janssen develop one of the first antipsychotics

2002

Janssen receive approval for the first atypical long-acting treatment for schizophrenia

2016

Janssen receive approval for the first three-monthly long-acting therapy for schizophrenia in adults⁴

2018

Janssen proudly mark the 60th year of continued dedication to the area of mental health

2019

Janssen receive approval for an anti-depressant nasal spray with the first different mechanism of action in over 30 years⁵

2021

Janssen receive approval for a once-daily disease-modifying therapy for relapsing multiple sclerosis⁶

Janssen: Our commitment to Neuroscience

Achieving success through collaboration



Through lasting partnerships, **we harness the world’s best scientific expertise** to continue transforming lives through pioneering therapies and solutions.

Our commitment to collaboration in numbers:



4 Innovation Centres
 focussing on early-stage partnerships across key therapy areas



12 Janssen Laboratories
 focussing on developing and accelerating emerging health technologies

Holding patients and carers at our core

We work in partnership with the patient community to **understand their everyday realities and make a real impact** on individual lives.

Across our Neuroscience portfolio, we have:



Supported more than **30 patient and carer organisations** across Europe



Created **practical tools and public initiatives** to help patients better understand and manage their neurological conditions



Worked to **empower those living with neurological conditions** to start meaningful conversations about their conditions



“We are revolutionising how we think of, and treat, nervous system disorders. In the words of Dr Paul Janssen: ‘the patients are waiting’. Through in-house discovery and strategic partnerships, we will lead the new era of neuroscience precision medicine so we can continue to make a real impact on patients’ lives.”

Tamara Werner-Kiechle,
 EMEA Therapeutics Area Lead,
 CNS and Pulmonary Hypertension

References

1. Deuschl G, et al. Fact sheet: The burden of neurological diseases on Europe. Available at: https://www.ean.org/fileadmin/user_upload/ean/research/Fact_sheet_about_neurological_diseases_Europe_06112019.pdf. Last accessed October 2021.
2. Deuschl G, et al. The burden of neurological diseases in Europe: an analysis for the Global Burden of Disease Study 2017. Lancet Public Health. 2020;5(10), E551-E567.
3. Janssen. 2019. Psychiatry: Mood Disorders Portfolio. Data on file. PSY/DOF/MAY2019/EMEA001.
4. Janssen. Press release on May 2016. Available at: http://www.janssen.com/emea/sites/www_janssen_com_emea/files/trevicta_ec_press_release_v11_31_05_16_emea_uk.pdf. Last accessed October 2021.
5. Janssen. Press release on December 2019. Available at: https://www.janssen.com/emea/sites/www_janssen_com_emea/files/spravatorov_esketamine_nasal_spray_approved_in_europe_for_adults_with_treatment-resistant_major_depressive_disorder.pdf. Last accessed October 2021.
6. Janssen. Press release on March 2021. Available at: https://www.janssen.com/emea/sites/www_janssen_com_emea/files/european_commission_approves_ponvorytm_ponesimod_a_once_daily_oral_therapy_for_the_treatment_of_adults_with_relapsing_forms_of_multiple_sclerosis_with_active_disease_defined_by_clinical_or_imaging_features.pdf. Last accessed October 2021.